Alzamend Neuro, Inc.
ALZN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.13
KIRA · Stoqly’s AI analyst, in plain words
- Alzamend Neuro, Inc. lost $8.8M in fiscal 2026.
Market cap
$5.1M
P/E
—
Revenue
—
Net income
−$8.8M
Free cash flow
—
Operating margin
—
Alzamend Neuro, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$8.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Alzamend Neuro, Inc. does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 22, 2026
- Legal name
- Alzamend Neuro, Inc.
- CIK
- 0001677077
Alzamend Neuro, Inc. · ALZN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.4M | −$14.9M | −$9.9M | −$4.5M | −$8.8M |
| Diluted EPS | −$0.14 | −$22.89 | −$132.33 | −$11.32 | −$2.63 |
| Cash | |||||
| Cash from operations | −$6.6M | −$8.9M | −$8.3M | −$6.6M | −$8.1M |
| Share count change | 22.6% | −99.3% | −88.6% | 507.5% | 640.3% |
| Debt and strength | |||||
| Cash and short-term investments | $14.1M | $5.1M | $0.4M | $3.9M | $0.7M |
| Shareholders' equity | $13.4M | $3.0M | −$2.6M | $4.0M | $0.7M |
| Current ratio | 12.4x | 2.0x | — | — | — |
| Interest coverage | −264.9x | −1,931.2x | −983.9x | −249.8x | −1,328.3x |
| Returns and quality | |||||
| Return on equity | −160.9% | −181.5% | −4,408.5% | −657.2% | −373.2% |
| Return on tangible equity | −92.6% | −488.5% | — | −128.7% | −1,196.5% |
| Altman Z'' | 5.8 | −36.8 | — | — | — |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alzamend Neuro, Inc. · ALZN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.13 a share, the company is worth $5.1M.
Source: SEC EDGAR XBRL filings (CIK 0001677077). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.